NCT07274137

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of MDR-001 Administered Orally Over 52 Weeks in Participants With Overweight or Obesity (MOBILE)

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 738 (estimated)
• Sponsor: MindRank AI Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	MDR-001	Participants will Receive Small Molecule MDR-001 Tablets Administered Orally
DRUG	Placebo	Participants will Receive Placebo

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-06-01
• Completion: 2027-07-01
• First posted: 2025-12-10
• Last updated: 2025-12-22

Locations

45 sites across 1 country: China